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Abstract 
Background: Hepatitis B virus (HBV) is highly contagious and causes liver diseases. Globally more than 350 million 
people are chronically infected and among them above 80 % are from developing countries like Bangladesh. Resist-
ance to existing drugs and vaccines are common phenomenon due to mutations in HBsAg ‘a’ determinant. Due to 
lack of data about mutations and subtypes of HBV in Bangladesh, this study strongly demands to be documented. 
Here, we determined the genotypes and subtypes of HBV prevalent in Bangladesh, and their genomic mutations 
associated with vaccine and drug resistance.
Results: Among 385 samples, a total of 54 (14 %) were found HBV positive, of which 19 samples were subjected 
to be sequenced. After bioinformatic analysis, we found Genotype D as predominant genotype (73.7 %) with sub-
types ayw3 (64.3 %) and ayw2 (35.7 %), followed by genotype A with subtype adw2 (15.8 %), and then genotype C 
with subtype adr (10.5 %). A significant number of mutations (Thr118Val, Thr125Met, Thr126Ile, Pro127Thr, Ala128Val, 
Thr131Asn/Ser, Thr/Ser143Leu/Met) were found in ‘a’ determinant region which may admit resistance to the available 
vaccines and failure of HBsAg detection.
Conclusions: This comprehensive study have clinical importance like disease diagnosis and treatment. It emphasizes 
HBV infected patients to do molecular diagnosis for choice of anti-viral drugs and effectiveness of vaccines for proper 
treatment.
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Background
Hepatitis B virus (HBV) infects over 350 million people 
globally per year and causes serious acute and chronic 
liver diseases (Mast et al. 2005; Norder et al. 1993, 1994). 
Globally, more than 300  million people have chronic 
HBV infection and approximately two billion are infected 
(Scheiblauer et  al. 2010; Shaha et  al. 2015). HBV inte-
grates its genome into liver cell and can reside there for 
long time which is seem to develop HBV carrier state 
and thereby, may cause damage to the liver permanently 
(Suppiah et  al. 2014). In Bangladesh, HBV is one of the 
major causes of hepatocellular carcinoma (HCC), which 
is known to be a leading cause of death in the world (Sup-
piah et al. 2014).
Genomic variation of HBV genotypes is determined by 
genomic relatedness, where the standard cut-off of diver-
gence is about 8  % (Bowyer and Sim 2000). In Bangla-
desh, the most prevalent genotype is genotype C among 
the chronic infection of HBV in one study (Rahman et al. 
2016) and genotype D among the patients with chronic 
infection in a tertiary-care hospital in another study 
(Mamun Al et  al. 2006); however the data on subtypes 
and mutations in surface (S) gene that contains ‘a’ deter-
minant region are not available. The HBsAg ‘a’ deter-
minant region is located between amino acids 124–147 
within the major hydrophilic region (MHR amino acids 
99–169) of this S gene encoded protein (Velu et al. 2008). 
Genotyping and Subtyping of HBV is totally based on 
increasing of variety of antibodies to the ‘a’ determinant 
(Moradi et al. 2012). Mutations in this region causes vac-
cine escape as well as HBsAg detection failure mutants 
through alteration of antigenicity of the protein (Carman 
et al. 1990).
Open Access
*Correspondence:  msshaha@nib.gov.bd 
1 Microbial Biotechnology Division, National Institute of Biotechnology, 
Savar, Dhaka 1349, Bangladesh
Full list of author information is available at the end of the article
Page 2 of 7Shaha et al. SpringerPlus  (2016) 5:1513 
On the other hand, drug resistance can be caused due 
to high mutation rate of polymerase gene, which made 
HBV infection unpreventable even after vaccination. 
These mutations can be raised mostly among chronic 
patients who take anti-viral drugs regularly. Vaccine and 
anti-viral drug resistance have been described as signifi-
cant factors to treatment failure of hepatitis B as stated 
by Locarnini and Mason (Locarnini and Mason 2006).
Sequencing part of surface gene from 370 to 861  nt 
(491 bp) can be termed as partial S gene sequencing that 
can reveal genotyping, subtyping and common muta-
tions as efficiently as total S gene sequencing (Wang et al. 
2013). This small part of the S gene is conserved and con-
tains ‘a’ determinant region as well as many drug resist-
ant and vaccine mutant sites (Wang et al. 2013). Recent 
reports in different areas of the world, showing the anti-
viral drugs resistant strains of HBV, strongly alert the 
need for monitoring drug resistant and vaccine mutant 
sites along with mutations in other genes of the genome 
of HBV (Sayan et al. 2010; Pastor et al. 2009; Han et al. 
2009). Herein, we analyzed the partial S gene to deter-
mine the genotypes, subtypes and possible mutations in 
partial S gene of HBV genome through polymerase chain 
reaction (PCR) and sequencing.
Methods
Sample selection
A total of 385 patients with jaundice like illness were 
included in this study and blood samples were collected 
from different medical college hospitals of Dhaka city. 
This study was ethically cleared by ethical committee of 
Dhaka Medical College, Dhaka-1000, Bangladesh (refer-
ence number: DMC-MEU/ECC/2014/16). The samples 
were collected after obtaining a written consent from 
every patient. None of the patients were HBV vaccinated. 
We selected the patients with jaundice like illness who 
might have been infected by hepatitis B viruses because 
jaundice is one of the main symptoms of hepatitis B 
infection.
Serological analysis
Serum samples were allowed to be clotted for approxi-
mately 10 min and centrifuged at 5000 rpm for 5 min to 
separate serum from blood. The obtained serum sam-
ples were subjected to analyze Hepatitis B surface anti-
gen (HBsAg) by Enzyme Linked Immune Sorbent Assay 
(ELISA) using ELISA kits (JAJ International Inc., CA, 
USA).
DNA extraction
HBV-DNA of several randomly selected HBsAg positive 
samples was extracted from 200 µl of plasma using path-
ogen kit (Stratec molecular, Berlin, Germany) according 
to manufacturer’s instruction. Extracted DNA was stored 
at −20 °C until use.
Polymerase chain reaction and DNA amplification
Partial S gene was targeted to be amplified in this study. 
A product of 491 base pairs of partial S gene was ampli-
fied using 5′-TCGCTGGATGTGTCTGCGGCGTTT 
TAT-3′ and 5′-ACCCCATCTTTTTGTTTTGTTAGG-3′ 
primer pair as forward and reverse primers respectively 
corresponding to nucleotide position 370–861 (Wang 
et  al. 2013). Four microliter (µl) of extracted DNA was 
added into the mixture containing 12.5  µl of 2×  MiFi 
Mix, 1.0 µl of each primer (10 pmol) and 6.5 µl nuclease 
free water making total volume of 25  µl reaction. Then 
the mixture was amplified using a PCR protocol as fol-
lows: 12 min at 95 °C, 35 cycles of 1 min at 94 °C, 1 min 
at 52  °C, 1  min at 72  °C, and a final elongation step of 
7 min at 72 °C. The amplification products of 491 bp were 
analyzed by agarose gel electrophoresis (AGE) on 1.5  % 
agarose gel stained with ethidium bromide to observe 
HBV-DNA positive and negative samples, and viewed 
under UV illumination.
Post PCR purification and sequence determination
The corresponding amplicons were purified using the 
PCR clean-up system (Promega Corporation, Madison, 
WI, USA) according to the manufacturer’s instruction. 
Final elution contained 50  µl of purified PCR products 
from which 10 µl was reanalyzed on 1.5 % agarose gel to 
make sure that the purification step was performed pre-
cisely. Sequencing was done with the same primers used 
to amplify the 491 bp partial S gene sequences.
Determination of genotypes and subtypes
After obtaining the sequences of partial S gene, NCBI-
BLAST (BLASTn) was performed to get the sequence 
similarity with other sequences deposited in the NCBI 
site. The sequences were also analyzed using EMBOSS 
Transeq tool of EMBL-EBI server (McWilliam et  al. 
2013) to find all six frames of in silico translation of pro-
teins and subjected to protein BLAST (PSI) against NCBI 
protein database to find the correct open reading frame 
(ORF) of the translated protein. Experimental sequences 
were aligned using MEGA version 5 tools (Tamura et al. 
2011) and genotypes were determined by constructing 
phylogenetic tree. Phylogenetic tree was constructed 
by Maximum Likelihood Statistical Method with boot-
strap replication of 100 times and analysed using Kimura 
2-parameter model with uniform rates among sites. 
The obtained sequences were aligned by Clustal Omega 
method (Larkin et al. 2007). The reference sequences for 
this alignment were local and foreign S gene sequences 
collected from NCBI GeneBank.
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Analysis of mutations
For analyzing respective mutations that are associ-
ated with resistance to vaccine and anti-viral drugs 
the sequences were aligned with standard hepatitis B 
sequence (Accession number: AB033559) from GenBank 
database (Moradi et al. 2012) by MEGA version 5 software 
(Tamura et al. 2011) and visualized using Jalview software 
(Waterhouse et  al. 2009). Amino acid codons 122, 160, 
127, 159 and 140 of S gene were used to predict HBsAg 
subtypes as described elsewhere (Purdy et al. 2007).
Sequence deposition
Partial CDS of S gene sequences is deposited in GenBank 
under accession numbers: KP240636–KP240654.
Results
Genotype D as most prevalent genotype in Bangladesh
A total of 54 (14 %) samples were observed HBsAg posi-
tive. Among them 19 samples were randomly selected 
to be analyzed by PCR and then nucleotide sequencing. 
After phylogenetic analysis, 14 (73.7  %) samples were 
found as genotype D, followed by genotype A (15.8  %) 
and then genotype C (10.5 %). Phylogenetic tree revealed 
the similarity of these sequences varying regionally across 
the world. Furthermore, genotype D was comprised of 
two subtypes namely, ayw3 (64.3  %) and ayw2 (35.7  %), 
whereas, subtype adw2 and adr were specific for genotype 
A and genotype C respectively as shown in Fig. 1.
Evolutionary relationship of our HBV with other circulating 
HBVs
After constructing phylogenetic tree, we observed strong 
similarity of our partial S protein sequence with other Bang-
ladeshi sequences (up to 97  %) and sequences from India 
(up to 100 %) and Malaysia (96 %) as shown in Fig. 2. How-
ever, sequences comprising genotype D were evolutionar-
ily diverted (Fig. 2). On the other hand, there were several 
amino acid mutations like K122R (amino acid Lysine at 
122 position of S protein instead of Arginine), T131S and 
I208T in genotype C (Fig.  3). The above mutations might 
have possible effect on structural and functional activity of 
S protein which might be a significant cause of resistance. 
Phylogenetic tree of above alignment revealed that our 
sequences were closely related with other Bangladeshi exist-
ing sequences with a similarity of more than 90 % (Fig. 2a). 
Phylogenetic analysis revealed the highest similarity of gen-
otype A, C and D sequences with the sequences from India, 
Malaysia and India respectively (Fig. 2b).
Multiple mutations of our sequences in ‘a’ determinant 
region
Several mutations were observed in ‘a’ determinant 
region of S gene such as, T118V, T125M, T126I, P127T, 
A128V and T/S143L/M according to different genotypes 
of HBV (Table 1). These mutations probably have strong 
impact on functions of S gene especially resistance to dif-
ferent drugs as well as vaccine.
Discussion
As the severity of HBV is increasing day by day and 
resistance to the anti-viral drugs and vaccines is raising 
exponentially, it is essential to demonstrate the mutation 
status of HBV genome across the world. Hence, the pur-
pose of this study was to determine the genotypes and 
subtypes of HBV prevailing in Bangladesh and to dem-
onstrate possible mutations in ‘a’ determinant region that 
might be responsible for resistance to different anti-viral 
drugs and vaccines.
In this study, we found genotype D (73.7  %) as most 
prevalent in Bangladesh, followed by genotype A (15.8 %) 
and then genotype C (10.5  %), which is consistent with 
other study done in India (Ismail et al. 2012). We used dif-
ferent existing Bangladeshi and foreign sequences of dif-
ferent genotypes as well as a standard GenBank sequence 
(Accession number: AB033559) (Moradi et al. 2012) from 
NCBI GenBank to determine the genotypes in Bangla-
desh and aligned the sequences of those genotypes to 
observe subtypes. In Bangladesh, the predominant sub-
types associated with genotype D are ayw3 (64.3  %) and 
ayw2 (35.7  %), and subtypes adw2 and adr were specific 
for genotype A and C respectively. One previous study 
in Bangladesh documented the predominant genotype in 
Bangladesh is genotype D which was in accordance with 
our study (Mahtab et al. 2008; Mamun Al et al. 2006).
We demonstrated several amino acid variations in 
genotypes A, C and D comparing with the previously 
documented NCBI sequences. Whereas, genotype A was 
Fig. 1 Distribution of HBV genotypes in Bangladesh
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Fig. 2 Phylogenetic analysis of HBV sequences with a different existing Bangladeshi strains and b foreign strains collected from NCBI GenBank. Our 
experimental sequences have been marked with boxes
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more conserved than genotypes C and D as shown in 
Fig. 3. Genotype D was found more susceptible to surface 
gene mutations (Table 1).
The highest similarity of genotype A and D was found 
with the sequences from India. However, genotype 
C was found most similar with the sequences from 
Malaysia, which are highly communicated countries by 
Bangladesh.
The genomic mutation in partial S region of HBV 
have clinical importance. Mutations in ‘a’ determinant 
region are associated with functional properties of HBV 
as described above. Different mutations in ‘a’ determi-
nant were found in our sequences as shown in Table  1. 
Among which, Thr118Val, Thr125Met, Pro127Thr, 
Ala128Val and Thr/Ser143Leu/Met were observed in 
genotype D sequences, which is thought to have strong 
impacts on functions of S gene. For example, substitu-
tion Pro127Thr has been alarmed as great public health 
significance. Patients with this mutation lack to exhibit 
quantifiable HBsAg as declared in different studies 
(Simon et al. 2013; Scheiblauer et al. 2010). Furthermore, 
Sequences of genotype C were found to have Thr126Ile 
and Thr131Ser mutations, and genotype A sequences 
have only Thr131Asn mutation in ‘a’ determinant region. 
Although activity of these mutations was not docu-
mented, they might lead to the conformational change of 
‘a’ determinant region and as a result, vaccine would be 
less immunogenic to induce an antibody response even 
after complete vaccination. Hence, this study recommend 
to demonstrate experimentally whether these mutations 
have any resistant property to anti-viral drug or vaccine.
Conclusions
This study is unique for three reasons (1) a detail mutation 
profile of ‘a’ determinant region of S gene was delineated 
(2) amino acid comparison of our sequences with different 
existing Bangladeshi and foreign sequences was described 
and lastly (3) this is the first comprehensive study detecting 
the mutations and subtypes of HBV in Bangladesh. This 
study has the importance to direct clinicians to diagnose 
Fig. 3 Alignment of HBV sequences with a different Bangladeshi strains and b foreign strains. Our experimental sequences have been marked 
with boxes. Matched amino acids were presented as dot and mismatched were shown in symbols. Alignment was done by MEGA v5.0 software and 
visualized using Jalview v2.8.1 software
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Table 1 Possible mutations in ‘a’ determinant region in the 









D KP240636 No mutations
KP240637 No mutations
KP240638 Thr118Val, Pro127Thr, Ala128Val
KP240639 No mutations




KP240647 Thr118Val, Pro127Thr, Ala128Val
KP240648 Thr118Val, Pro127Thr, Ala128Val
KP240649 Thr118Val, Pro127Thr, Ala128Val, 
Thr/Ser143Leu/Met
KP240651 Thr118Val, Pro127Thr, Ala128Val
KP240653 Thr118Val, Pro127Thr, Ala128Val
KP240654 Thr118Val, Pro127Thr, Ala128Val
the disease properly and decide the choice of drugs or vac-
cines for the treatment of hepatitis B and HBV carriers.
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